Vaxart, Inc. Loss Contingency, Loss in Period
Vaxart, Inc. (VXRT) reported Loss Contingency, Loss in Period of $1.70 million for the 1-month period ending 2011-12-31, per its 10-Q filed 2012-11-08.
Discontinued › Notes
us-gaap:LossContingencyLossInPeriod · last filed 2012-11-08
- 2011-12-31: Loss Contingency, Loss in Period 1 month $1.70M.
| Period end | Loss Contingency, Loss in Period 1 month |
|---|---|
| 2011-12-31 | $1.70M 10-Q · filed 2012-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |